0
Editorials |

Treatment of Pulmonary Arterial Hypertension: A Step Forward

Sat Sharma
Author and Funding Information

Affiliations: Boniface General Hospital, Winnipeg, MB, Canada
 ,  Dr. Sharma is Assistant Professor, Sections of Pulmonary Medicine and Critical Care, University of Manitoba.

Correspondence to: Sat Sharma, MD, FCCP, Site Coordinator, Department of Respiratory Medicine, St. Boniface General Hospital, BG034-409 Tache Ave, Winnipeg, MB, Canada R2H 2A6; e-mail: ssharma@sbgh.mb.ca



Chest. 2003;124(1):8-11. doi:10.1378/chest.124.1.8
Text Size: A A A
Published online

Extract

Pulmonary arterial hypertension (PAH) is characterized by progressive obliteration of the pulmonary vascular bed. If untreated, PAH progresses to death from right-heart failure. Median survival is < 2 years following diagnosis. PAH is characterized by vasospasm, intimal fibrosis, thrombosis in situ, proliferation of smooth muscles, and medial hypertrophy; plexogenic arteriopathy is the pathologic hallmark of this disorder.1 Similar vascular lesions, clinical picture, and natural history are encountered in many other conditions, including collagen vascular diseases, portal hypertension, HIV infection, and exposure to anorectic drugs. The new classification scheme incorporates pulmonary hypertension (PH) associated with these illnesses and primary PH (PPH) as types of PAH.2 Advances in understanding of pathogenesis of PAH, along with cellular and molecular research, have led to the development of newer approaches to treatment for a disease previously considered untreatable.

First Page Preview

View Large
First page PDF preview

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543